Summary
Strong evidence has accumulated on the prognostic value of tumour-associated proteolytic factors in patients afflicted with solid malignant tumours, including advanced ovarian cancer. We evaluated the prognostic impact of the protease urokinase plasminogen activator (uPA) and its inhibitor PAI-1 on overall survival in patients with advanced ovarian cancer stage FIGO IIIc in order to select patients at risk. uPA and PAI-1 antigen were determined by ELISA in primary tumour tissue extracts of 86 ovarian cancer patients FIGO stage IIIc enrolled in a prospective study. Univariate and multivariate analyses were performed using the Cox proportional hazard model. The time-varying coefficient model of Gray was used to assess the time-dependent strength of prognostic factors tumour mass, uPA and PAI-1 on overall survival. In all patients, uPA and PAI-1 (optimized cut-offs of 2.0 and 27.5 ng mg-1 protein respectively), in addition to the traditional prognostic parameters of residual tumour mass, nodal status, grading and ascites volume, were of prognostic significance in univariate analysis for overall survival. Even in patients with residual tumour mass (n = 43), the statistically independent prognostic impact of PAI-1 persisted, allowing further discrimination between low- and high-risk patients. In multivariate analysis, residual tumour mass (P < 0.001, relative risk (RR) 4.5), PAI-1 (P < 0.001; RR 3.1) and nodal status (P = 0.022, RR 2.6) turned out to be strong, statistically independent prognostic parameters. Evaluation of the time-dependent prognostic impact of residual tumour mass and PAI-1 on overall survival (n = 86, 50 months) revealed that the prognostic power of these factors increased with time. In patients with advanced ovarian cancer, both residual tumour mass and PAI-1 are statistically independent strong prognostic factors. Even within patient subgroups with or without residual tumour mass, PAI-1 allowed selection of patients at risk who might benefit from individualized therapy protocols.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Astedt, B. & Holmberg, L. (1976). Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 261: 595–597.
Barbareschi, M., Gasparini, G., Morelli, L., Forti, S. & Della-Palma, P. (1995). Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res Treat 36: 181–192.
Benedetti, P. P., Greggi, S., Scambia, G., Salerno, M. G., Baiocchi, G., Laurelli, G., Menichella, G., Pierelli, L., Foddai, M. L. & Serfaini, R. (1995). Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Eur J Cancer 31A: 1987–1992.
Bertelsen, K. (1990). Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 38: 203–209.
Berchuck, A., Rodriguez, G. C., Kamel, A., Dodge, R. K., Soper, J. T., Clarke-Pearson, D. L. & Bast, R. C. Jr (1991). Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Am J Obstet Gynecol 164: 669–674.
Burghardt, E., Girardi, F., Lahousen, M., Tamussino, K. & Stettner, H. (1991). Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 40: 103–106.
Casslen, B., Bossmar, T., Lecander, I. & Astedt, B. (1994). Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 30: 1302–1311.
Conese, M. & Blasi, F. (1995). Urokinase/urokinase receptor system: Internalization/ degradation of urokinase-serpin complexes: mechanism and regulation. Biol Chem Hoppe-Seyler 376: 143–155.
Danø, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S. & Skriver, L. (1985). Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139–266.
Dettmar, P., Harbeck, N., Thomssen, C., Pache, L., Ziffer, P., Fizi, K., Jänicke, F., Nathrath, W., Schmitt, M., Graeff, H. & Höfler, H. (1997). Prognostic impact of proliferation-associated factors MIBl (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 75: 1525–1533.
Duffy, M. J., Reilley, D., O’Sullivan, C., O’Higgins, N., Fennelly, J. J. & Andreasen, P. (1990). Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827–6829.
Foekens, J. A., Schmitt, M., van Putten, W. L. J., Peters, H. A., Bontenbal, M., Jänicke, F. & Klijn, J. G. (1992). Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101–6105.
Friedlander, M. L., Quinn, M. A., Fortune, D., Foo, M. S., Toppila, M., Hudson, C. N. & Russell, P. (1989). The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors. Gynecol Oncol 32: 184–190.
Gray, R. J. (1992). Flexible methods for analyzing survival data using splines, with application to breast cancer prognosis. J Am Stat Assoc 87: 942–951.
Griffiths, C. T., Parker, L. M. & Fuller, A. F. Jr (1979). Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Reports 63: 235–240.
Grøndahl-Hansen, J., Christensen, I. J., Rosenquist, C., Brünner, N., Mouridsen, H. T., Danø, K. & Blichert-Toft, M. (1993). High levels of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513–2521.
Heintz, A. P. M., Hacker, N. F., Berek, J. S., Rose, T. P., Munoz, A. K. & Lagasse, L. D. (1986). Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 67: 783–788.
Hofmann, R., Lehmer, A., Buresch, M., Hartung, R. & Ulm, K. (1996). Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 78: 487–492.
Jänicke, F., Schmitt, M., Ulm, K., Gössner, W. & Graeff, H. (1989). Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 8670: 1049
Jänicke, F., Hölscher, M., Kuhn, W., von Hugo, R., Pache, L., Siewert, J. R. & Graeff, H. (1992). Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70: 2129–3216.
Kaern, J., Trope, C. G., Kristensen, G. B. & Pettersen, E. O. (1994). Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma. Cancer 73: 1870–1877.
Kanse, S., Kost, C., Wilhelm, O., Andreasen, P. & Preissner, K. (1996). The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 224: 344–353.
Kaplan, E. L. & Meier, P. (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Kigawa, J., Minagawa, Y., Ishihara, H., Kanamori, Y. & Terakawa, N. (1993). Tumor DNA ploidy of patients with serous cystadenocarcinoma of the ovary. Cancer 72: 804–808.
Kobayashi, H., Fujishiro, S. & Terao, T. (1994). Impact of urokinase-type plasminogen activator and its inhibitor type-1 on prognosis in cervical cancer of the uterus. Cancer Res 54: 6539–6548.
Kuhn, W., Jänicke, F., Pache, L., Hölscher, M., Schattenmann, G., Schmalfeldt, B., Anderl, H., Schüle, G., Dettmar, P., Siewert, J. R. & Graeff, H. (1993). Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III. Geburtshilf Frauenheilk 53: 293–302.
Kuhn, W., Pache, L., Schmalfeldt, B., Dettmar, P., Schmitt, M., Jänicke, F. & Graeff, H. (1994). Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401–409.
Kuhn, W., Florack, G., Roder, J., Schmalfeldt, B., Pache, L., Rust, M., Ulm, K., Späthe, K., Jänicke, F., Siewert, J. R. & Graeff, H. (1998). The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV. Int J Gynecol Cancer 8: 56–63.
Lage, J. M., Weinberg, D. S., Huettner, P. C. & Mark, S. D. (1992). Flow cytometric analysis of nuclear DNA content in ovarian tumors. Cancer 69: 2668–2675.
Liu, G., Shuman, M. A. & Cohen, R. L. (1995). Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60: 501–506.
Makar, A. P., Baekelandt, M., Trope, C. G. & Kristensen, G. B. (1995). The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56: 175–180.
Merkel, D. E. & McGuire, W. L. (1990). Ploidy, proliferative activity and prognosis. Cancer 65: 1194–1205.
Nekarda, H., Siewert, J. R., Schmitt, M., Roder J. D., Fink, U., Ulm, K., Becker, K. & Höfler, H. (1994). Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 343: 117
Pedersen, N., Schmitt, M., Rønne, E., Nicoletti, M. I., Hoyer-Hansen, G., Conese, M., Giavazzi, R., Dano, K., Kuhn, W. & Jänicke, F. (1993). A ligand-free, soluble urokinase receptor present in ascitic fluid from patients with ovarian cancer. J Clin Invest 92: 2160–2167.
Pujade-Lauraine, E., Lu, H., Mirshahi, S., Mirshahi, S., Soria, J., Soria, C., Bernadou, A., Kruithof, E. K., Lijnen, H. R. & Burtin, P. (1993). The plasminogen-activation system in ovarian tumors. Int J Cancer 55: 27–31.
Røldan, A. L., Cubellis, M. V., Masucci, M. T., Behrendt, N., Lund, L. R., Dano, K., Appella, E. & Blasi, F. (1990). Cloning and expression of the receptor for urokinase-type plasminogen activator, a central molecule in cell-surface plasmin-dependent proteolysis. EMBO J 9: 467–474.
Scarabelli, C., Gallo, A., Zarrelli, A., Visentin, C. & Campagnutta, E. (1995). Systemic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: Potential benefit on survival. Gynecol Oncol 56: 328–337.
Schmalfeldt, B., Kuhn, W., Reuning, U., Dettmar, P., Schmitt, M., Jänicke, F., Höfler, H. & Graeff, H. (1995). Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator (uPA), its receptor (uPAR) and inhibitors type-1 (PAI-1) and type-2 (PAI-2). Cancer Res 55: 3958–3963.
Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., Ulm, K., Höfler, H., Jänicke, F. & Graeff, H. (1997a). Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Hemost 78: 285–296.
Schmitt, M., Thomssen, C., Ulm, K., Seiderer, A., Harbeck, N., Höfler, H., Jänicke, F. & Graeff, H. (1997b). Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer 76: 306–311.
Sier, C. M., Vloedgraven, H. J. M., Ganesh, S., Griffioen, G., Quax, P. H., Verheijen, J. H., Dooijewaard, G., Welvaart, K., van de Velde, C. J. & Lamers, C. G. (1994). Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 107: 1449–1456.
Sier, C. M., Stephens, R., Biziki, J., Mariani, A., Bassan, M., Pedersen, N., Frigerio, L., Ferrari, A., Danø, K., Brünner, N. & Blasi, F. (1998). The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58: 1843–1849.
Stefansson, S. & Lawrence, D. A. (1996). The serpin PAI-1 inhibits cell migration by blocking integrin alpha(v)beta(3) binding to vitronectin. Nature 383: 441–443.
Tyson, F. L., Boyer, C. M., Kaufman, R., O’Briant, K., Cram, G., Crews, J. R., Soper, J. T., Daly, L., Fowler, W. C. Jr & Haskill, J. S. (1991). Expression and amplification of the HER2/neu (c-erbB2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol 165: 640–646.
Ulm, K., Dannegger, F., Klinger, A. & Jänicke, F. (1997). Zeitveränderliche Effekte prognostischer Faktoren am Beispiel des Mammakarzinoms. In Medizinische Informatik, Biometrie und Epidemiologie, Baur MP, Fimmers R and Blettner M (eds), pp. 447–450. MMV Verlag, München
Van der Burg, M. E. L., van Lent, M., Buyse, R., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J. & Pecorelli, S. (1995). The effect of debulking surgery after combination chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629–634.
Van der Burg, M. E. L., Henzen-Logmans, S. C., Berns, EMJJ, van Putten, W. L., Klijn, J. G. & Foekens, J. A. (1996). Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer 69: 475–479.
Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V. & Chapman, H. A. (1996). Regulation of integrin function by the urokinase receptor. Science 273: 1551–1555.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kuhn, W., Schmalfeldt, B., Reuning, U. et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79, 1746–1751 (1999). https://doi.org/10.1038/sj.bjc.6690278
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690278
Keywords
This article is cited by
-
Diabetes and ovarian cancer: risk factors, molecular mechanisms and impact on prognosis
Endocrine (2023)
-
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer
Journal of Cancer Research and Clinical Oncology (2020)
-
MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression
Journal of Experimental & Clinical Cancer Research (2016)
-
Clinical models and biochemical predictors of VTE in lung cancer
Cancer and Metastasis Reviews (2014)
-
Metastasis of ovarian cancer is mediated by kallikrein related peptidases
Clinical & Experimental Metastasis (2014)